Vanguard Group Inc Greenwich Life Sciences, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 223,102 shares of GLSI stock, worth $3.43 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

223,102

Previous 221,682 0.64%

Holding current value

$3.43 Million

Previous $2.33 Million 90.74%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$8.31 - $20.32 $11,800 - $28,854	1,420 Added 0.64%	223,102 $4.45 Million
Q4 2023 Feb 14, 2024	BUY	$7.77 - $12.3 $13,434 - $21,266	1,729 Added 0.79%	221,682 $2.33 Million
Q3 2023 Nov 14, 2023	SELL	$8.41 - $10.66 $523,623 - $663,712	-62,262 Reduced 22.06%	219,953 $1.94 Million
Q2 2023 Aug 14, 2023	SELL	$9.58 - $13.2 $671,644 - $925,438	-70,109 Reduced 19.9%	282,215 $2.72 Million
Q1 2023 May 15, 2023	BUY	$12.12 - $20.8 $94,536 - $162,240	7,800 Added 2.26%	352,324 $4.86 Million

Q4 2022 Feb 10, 2023	BUY	$9.04 - $16.88 $795 - $1,485	88 Added 0.03%	344,524 $5.24 Million
Q3 2022 Nov 14, 2022	SELL	$7.81 - $12.02 $76,538 - $117,796	-9,800 Reduced 2.77%	344,436 $3.13 Million
Q2 2022 Aug 12, 2022	SELL	$7.14 - $20.36 $149,682 - $426,827	-20,964 Reduced 5.59%	354,236 $3 Million
Q1 2022 May 13, 2022	BUY	$16.3 - $24.65 $3.67 Million - $5.55 Million	225,213 Added 150.16%	375,200 $7.36 Million
Q4 2021 Feb 14, 2022	BUY	$21.76 - $39.43 $15,079 - $27,324	693 Added 0.46%	149,987 $3.65 Million
Q3 2021 Nov 12, 2021	BUY	$38.65 - $46.11 $1.08 Million - $1.29 Million	27,876 Added 22.96%	149,294 $5.83 Million
Q2 2021 Aug 13, 2021	BUY	$31.24 - $53.6 $3.79 Million - $6.51 Million	121,418 New	121,418 $5.46 Million

Others Institutions Holding GLSI

# of Institutions

Shares Held

645K

Call Options Held

Put Options Held

View Full List

About Greenwich LifeSciences, Inc.

Ticker GLSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,848,200
Market Cap $198M
Description
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...

More about GLSI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Greenwich Life Sciences, Inc. Transaction History